INNOVENT BIO's match-patent for Bruton’s tyrosine kinase inhibitor has received official approval for new indications
INNOVENT BIO (01801.HK) announced that the non-covalent (reversible) Bruton tyrosine kinase (BTK) inhibitor, Jebatilib (Pirtobrutinib), has officially received approval from the National Medical Products Administration of China for a new indication, to be used in the treatment of adult patients with chronic lymphocytic leukemia/small lymphocytic lymphoma who have previously undergone at least one systemic therapy that included a BTK inhibitor
Source: AASTOCKS The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments